Bioasis announced on 29 June 2020 that it had entered into an agreement with Chiesi, in which it would license its technology to bypass the blood brain barrier (BBB), the xB3 platform, for the development of drugs targeting lysosomal storage disorders. Chiesi will use the platform to develop drugs for four disorders, and in return Bioasis will receive US$3m upfront, up to US$138m in additional milestones and undisclosed royalties. We see this as a major validation of the platform and for addi
02 Jul 2020
Bioasis Technologies - Platform licensed to Chiesi
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bioasis Technologies - Platform licensed to Chiesi
biOasis Technologies Inc. (BTI:TSX) | 0 0 0.0%
- Published:
02 Jul 2020 -
Author:
Dr Nathaniel Calloway -
Pages:
6
Bioasis announced on 29 June 2020 that it had entered into an agreement with Chiesi, in which it would license its technology to bypass the blood brain barrier (BBB), the xB3 platform, for the development of drugs targeting lysosomal storage disorders. Chiesi will use the platform to develop drugs for four disorders, and in return Bioasis will receive US$3m upfront, up to US$138m in additional milestones and undisclosed royalties. We see this as a major validation of the platform and for addi